SG11201501894VA - Tricyclic quinoline and quinoxaline derivatives - Google Patents
Tricyclic quinoline and quinoxaline derivativesInfo
- Publication number
- SG11201501894VA SG11201501894VA SG11201501894VA SG11201501894VA SG11201501894VA SG 11201501894V A SG11201501894V A SG 11201501894VA SG 11201501894V A SG11201501894V A SG 11201501894VA SG 11201501894V A SG11201501894V A SG 11201501894VA SG 11201501894V A SG11201501894V A SG 11201501894VA
- Authority
- SG
- Singapore
- Prior art keywords
- quinoxaline derivatives
- tricyclic quinoline
- tricyclic
- quinoline
- quinoxaline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/16—Peri-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261701531P | 2012-09-14 | 2012-09-14 | |
| US201261701514P | 2012-09-14 | 2012-09-14 | |
| US201361793033P | 2013-03-15 | 2013-03-15 | |
| CN201310410951.1A CN104418862A (en) | 2013-09-11 | 2013-09-11 | Tricyclic chinoline and quinoxaline derivatives |
| PCT/EP2013/069036 WO2014041131A1 (en) | 2012-09-14 | 2013-09-13 | Tricyclic quinoline and quinoxaline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201501894VA true SG11201501894VA (en) | 2015-04-29 |
Family
ID=50275085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201501894VA SG11201501894VA (en) | 2012-09-14 | 2013-09-13 | Tricyclic quinoline and quinoxaline derivatives |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10118926B2 (en) |
| EP (1) | EP2895485A1 (en) |
| JP (1) | JP6290217B2 (en) |
| KR (1) | KR20150056608A (en) |
| CN (1) | CN104995191A (en) |
| AR (1) | AR092568A1 (en) |
| AU (2) | AU2013314279B2 (en) |
| BR (1) | BR112015005743A2 (en) |
| CA (1) | CA2884548A1 (en) |
| CL (1) | CL2015000628A1 (en) |
| CR (1) | CR20150186A (en) |
| DO (1) | DOP2015000058A (en) |
| EC (1) | ECSP15012766A (en) |
| HK (1) | HK1212684A1 (en) |
| IL (1) | IL237726A0 (en) |
| IN (1) | IN2015DN02070A (en) |
| MX (1) | MX2015003364A (en) |
| NZ (1) | NZ631187A (en) |
| PE (1) | PE20150777A1 (en) |
| PH (1) | PH12015500551A1 (en) |
| RU (1) | RU2015113558A (en) |
| SG (1) | SG11201501894VA (en) |
| TW (1) | TW201414735A (en) |
| UA (1) | UA116216C2 (en) |
| UY (1) | UY35029A (en) |
| WO (1) | WO2014041131A1 (en) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI568722B (en) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | Triazolone compounds as mpges-1 inhibitors |
| JP6437452B2 (en) | 2013-01-14 | 2018-12-12 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| JP6554037B2 (en) | 2013-01-15 | 2019-07-31 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Thiazole carboxamide and pyridine carboxamide compounds useful as PIM kinase inhibitors |
| DK2968320T3 (en) | 2013-03-15 | 2021-02-01 | Intra Cellular Therapies Inc | ORGANIC COMPOUNDS |
| AU2014308703A1 (en) | 2013-08-23 | 2016-03-24 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as Pim kinase inhibitors |
| WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| JP6475727B2 (en) | 2013-12-03 | 2019-02-27 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | New method |
| US9573950B2 (en) | 2014-03-14 | 2017-02-21 | Abbvie Deutschland Gmbh & Co Kg | Substituted [1,4]diazepino[6,7,1-ij]quinolines as serotonin 5-HT2C receptor modulators |
| EP3116874B1 (en) | 2014-03-14 | 2018-02-28 | AbbVie Deutschland GmbH & Co. KG | Hexahydrodiazepinoquinolines carrying a substituted alkyl radical |
| BR112016023162B1 (en) | 2014-04-04 | 2022-11-29 | Intra-Cellular Therapies, Inc | ORGANIC GAMMA-CARBOLINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS INCLUDING SAID COMPOUNDS AND USE THEREOF IN THE TREATMENT OR PROPHYLAXIS OF CENTRAL NERVOUS SYSTEM DISORDERS |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| TWI734699B (en) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Salts of a pim kinase inhibitor |
| TW201718546A (en) | 2015-10-02 | 2017-06-01 | 英塞特公司 | Heterocyclic compounds useful as PIM kinase inhibitors |
| WO2017117514A1 (en) * | 2015-12-31 | 2017-07-06 | Tung Roger D | Deuterated iti-007 |
| RU2743513C2 (en) | 2016-01-26 | 2021-02-19 | Интра-Селлулар Терапиз, Инк. | Organic compounds |
| WO2017165755A1 (en) * | 2016-03-25 | 2017-09-28 | Intra-Cellular Therapies, Inc. | Organic compounds |
| PL3407889T3 (en) | 2016-03-25 | 2021-11-22 | Intra-Cellular Therapies, Inc. | Organic compounds and their use in treating or preventing central nervous system disorders |
| US10682354B2 (en) | 2016-03-28 | 2020-06-16 | Intra-Cellular Therapies, Inc. | Compositions and methods |
| EP3525763A4 (en) | 2016-10-12 | 2020-06-17 | Intra-Cellular Therapies, Inc. | Amorphous solid dispersions |
| US10906906B2 (en) | 2016-12-29 | 2021-02-02 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2018126140A1 (en) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| US20210009592A1 (en) * | 2018-03-23 | 2021-01-14 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2023068755A1 (en) * | 2021-10-18 | 2023-04-27 | 주식회사 사피엔스바이오 | Novel compound and pharmaceutical composition comprising same |
| KR102600176B1 (en) * | 2021-10-18 | 2023-11-10 | 주식회사 사피엔스바이오 | Novel compounds and pharmaceutical compositions comprising the same |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3714149A (en) | 1969-11-03 | 1973-01-30 | Upjohn Co | Pyridobenzodiazepinones |
| JP2955358B2 (en) | 1989-06-09 | 1999-10-04 | ファルマシア・アンド・アップジョン・カンパニー | Heterocyclic amines with central nervous system activity |
| MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
| US6277985B1 (en) | 1995-09-15 | 2001-08-21 | Pharmacia & Upjohn Company | Aminoaryl oxazolidinone N-oxides |
| ZA9711274B (en) * | 1996-12-16 | 1998-06-23 | Warner Lambert Co | Tricyclic quinoxaline derivatives as neuroprotective agents. |
| US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
| AU2002227170A1 (en) * | 2000-11-03 | 2002-05-15 | Wyeth | Cycloalkyl(b)(1,4)diazepino(6,7,1-hi)indoles and derivatives |
| TWI312781B (en) * | 2002-04-25 | 2009-08-01 | [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents | |
| TW200307682A (en) | 2002-04-25 | 2003-12-16 | Wyeth Corp | 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents |
| US20080146583A1 (en) | 2003-05-15 | 2008-06-19 | Pfizer Inc | Treatment of Incontinence |
| US7307163B2 (en) | 2004-04-19 | 2007-12-11 | Symed Labs Limited | Process for the preparation of linezolid and related compounds |
| EP1768967B1 (en) | 2004-07-20 | 2009-04-22 | Symed Labs Limited | Novel intermediates for linezolid and related compounds |
| US7511013B2 (en) | 2004-09-29 | 2009-03-31 | Amr Technology, Inc. | Cyclosporin analogues and their pharmaceutical uses |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
| WO2007112073A2 (en) | 2006-03-24 | 2007-10-04 | Wyeth | Methods for modulating bladder function |
| CA2644662A1 (en) | 2006-03-24 | 2007-10-04 | Wyeth | New therapeutic combinations for the treatment of depression |
| WO2007112000A2 (en) * | 2006-03-24 | 2007-10-04 | Wyeth | Treatment of pain |
| US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
| KR101222412B1 (en) | 2007-02-15 | 2013-01-15 | 에프. 호프만-라 로슈 아게 | 2-aminooxazolines as taar1 ligands |
| KR20100012031A (en) | 2007-04-19 | 2010-02-04 | 콘서트 파마슈티컬즈, 인크. | Deuterated morpholinyl compounds |
| US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
| US20090131485A1 (en) | 2007-09-10 | 2009-05-21 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
| US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
| US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
| WO2009045476A1 (en) | 2007-10-02 | 2009-04-09 | Concert Pharmaceuticals, Inc. | Pyrimidinedione derivatives |
| US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
| EP2212298B1 (en) | 2007-10-18 | 2013-03-27 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
| CA2703591C (en) | 2007-10-26 | 2013-05-07 | Concert Pharmaceuticals, Inc. | Deuterated darunavir |
| EP2522671B1 (en) * | 2009-04-23 | 2016-01-20 | AbbVie Inc. | Modulators of 5-HT receptors and methods of use thereof |
| US20140080813A1 (en) * | 2012-09-14 | 2014-03-20 | AbbVie Deutschland GmbH & Co. KG | Tricyclic quinoline and quinoxaline derivatives |
-
2013
- 2013-09-13 NZ NZ631187A patent/NZ631187A/en not_active IP Right Cessation
- 2013-09-13 UA UAA201503409A patent/UA116216C2/en unknown
- 2013-09-13 AR ARP130103294A patent/AR092568A1/en unknown
- 2013-09-13 US US14/026,354 patent/US10118926B2/en active Active
- 2013-09-13 SG SG11201501894VA patent/SG11201501894VA/en unknown
- 2013-09-13 CN CN201380059579.2A patent/CN104995191A/en active Pending
- 2013-09-13 BR BR112015005743A patent/BR112015005743A2/en not_active IP Right Cessation
- 2013-09-13 PE PE2015000363A patent/PE20150777A1/en not_active Application Discontinuation
- 2013-09-13 IN IN2070DEN2015 patent/IN2015DN02070A/en unknown
- 2013-09-13 WO PCT/EP2013/069036 patent/WO2014041131A1/en active Application Filing
- 2013-09-13 UY UY0001035029A patent/UY35029A/en not_active Application Discontinuation
- 2013-09-13 MX MX2015003364A patent/MX2015003364A/en unknown
- 2013-09-13 EP EP13762483.9A patent/EP2895485A1/en not_active Withdrawn
- 2013-09-13 CA CA2884548A patent/CA2884548A1/en not_active Abandoned
- 2013-09-13 AU AU2013314279A patent/AU2013314279B2/en not_active Ceased
- 2013-09-13 RU RU2015113558A patent/RU2015113558A/en not_active Application Discontinuation
- 2013-09-13 KR KR1020157009502A patent/KR20150056608A/en not_active Application Discontinuation
- 2013-09-13 JP JP2015531577A patent/JP6290217B2/en not_active Expired - Fee Related
- 2013-09-14 TW TW102133403A patent/TW201414735A/en unknown
-
2015
- 2015-03-12 IL IL237726A patent/IL237726A0/en unknown
- 2015-03-13 PH PH12015500551A patent/PH12015500551A1/en unknown
- 2015-03-13 DO DO2015000058A patent/DOP2015000058A/en unknown
- 2015-03-13 CL CL2015000628A patent/CL2015000628A1/en unknown
- 2015-04-01 EC ECIEPI201512766A patent/ECSP15012766A/en unknown
- 2015-04-10 CR CR20150186A patent/CR20150186A/en unknown
-
2016
- 2016-01-18 HK HK16100520.1A patent/HK1212684A1/en unknown
-
2018
- 2018-01-24 AU AU2018200572A patent/AU2018200572A1/en not_active Abandoned
- 2018-11-02 US US16/179,050 patent/US20190071443A1/en not_active Abandoned
-
2019
- 2019-10-14 US US16/601,075 patent/US20200283439A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20140080816A1 (en) | 2014-03-20 |
| IN2015DN02070A (en) | 2015-08-14 |
| PH12015500551A1 (en) | 2015-05-04 |
| US10118926B2 (en) | 2018-11-06 |
| UY35029A (en) | 2014-04-30 |
| AR092568A1 (en) | 2015-04-22 |
| EP2895485A1 (en) | 2015-07-22 |
| KR20150056608A (en) | 2015-05-26 |
| AU2013314279B2 (en) | 2017-11-02 |
| IL237726A0 (en) | 2015-05-31 |
| JP6290217B2 (en) | 2018-03-07 |
| BR112015005743A2 (en) | 2017-07-04 |
| US20190071443A1 (en) | 2019-03-07 |
| CN104995191A (en) | 2015-10-21 |
| AU2018200572A1 (en) | 2018-02-15 |
| NZ631187A (en) | 2017-03-31 |
| CA2884548A1 (en) | 2014-03-20 |
| ECSP15012766A (en) | 2017-06-30 |
| UA116216C2 (en) | 2018-02-26 |
| PE20150777A1 (en) | 2015-06-20 |
| DOP2015000058A (en) | 2015-04-15 |
| CL2015000628A1 (en) | 2015-10-30 |
| MX2015003364A (en) | 2016-03-31 |
| WO2014041131A1 (en) | 2014-03-20 |
| AU2013314279A1 (en) | 2015-04-02 |
| RU2015113558A (en) | 2016-11-10 |
| US20200283439A1 (en) | 2020-09-10 |
| JP2015528478A (en) | 2015-09-28 |
| HK1212684A1 (en) | 2016-06-17 |
| TW201414735A (en) | 2014-04-16 |
| CR20150186A (en) | 2015-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1212684A1 (en) | Tricyclic quinoline and quinoxaline derivatives | |
| HK1211022A1 (en) | Novel quinolone derivatives | |
| HK1202545A1 (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
| IL236036A0 (en) | Pyridinone and pyridazione derivatives | |
| IL239369A0 (en) | Pirocyclic morphinans and their use | |
| HK1209106A1 (en) | (aza-)isoquinolinone derivatives (-) | |
| EP2828258A4 (en) | Novelpyridopyrimidine derivatives and use thereof | |
| HK1183301A1 (en) | Novel quinoline derivatives and their use thereof | |
| EP2822936A4 (en) | Aminoquinoline derivatives and uses thereof | |
| HK1202291A1 (en) | Isoquinoline and naphthyridine derivatives | |
| AP3611A (en) | Heterocyclic compounds and their uses | |
| HK1198833A1 (en) | N-acylpeptide derivatives and their uses n- | |
| HK1205514A1 (en) | Antibacterial quinoline derivatives | |
| HK1206727A1 (en) | Pyrazine derivatives | |
| EP2891343A4 (en) | Efficient proximity detection | |
| ZA201501640B (en) | Tricyclic tetrahydroquinoline antibacterial agents | |
| HK1202028A1 (en) | Probiotic antioxidant blend | |
| HK1201520A1 (en) | Antibacterial quinoline derivatives | |
| EP2752413A4 (en) | Quinazoline derivative and application thereof | |
| HK1184455A1 (en) | Quinoline derivatives and uses of the same | |
| GB201204745D0 (en) | Identifying proximity and location | |
| GB201202021D0 (en) | Co-sleeper and breastfeeder |